OTCQB:OPRX
Corporate Profile
March 2017
Leading EHR Aggregator Revolutionizing Pharma Marketing to HCP’s
OPRX Price & Volume
About OptimizeRx Corporation
OptimizeRx is a digital health company
with a proven ROI for marketing services
to the pharmaceutical industry.
We have exclusive partnerships with
electronic health and e-prescription
companies = powerful channel between
pharma companies and physicians.
Key Stats (Source: Company, FactSet)
Stock Price (3/7/17)
52 Week Low-High
Shares Outstanding
Public Float, est.
Market Cap
Avg. Daily Vol. (30 day)
Insider Holdings*
Strategic Ownership*
Institutional Holdings
Employees (@ 1/24/2017)
Revenue (ttm)
Net Loss (ttm)
Cash (as of Sept. 30)
Debt
Fiscal Year End
$0.85
$0.65-$1.20
29.7M
34%
$25.3M
27,098
~31%
~20%
~15%
21
$7.8M
$1.5M
$7.0M
$0
Dec. 31
Revenue Growth
($ in Millions)
$7.8 M
$6.5 M $7.2 M
$4.7 M
$1.1 M
11
$2.0 M
12
13
14
15
Company Contacts
William Febbo, CEO
Doug Baker, CFO
400 Water Street, Suite 200
Rochester, MI 48307
(248) 651-6568
Ron Both, Managing Partner
CMA
(949) 432-7557, [email protected]
16
OptimizeRx’s proprietary technology alerts
doctors of prescription savings &
automatically sends to pharmacies.
The channel allows physicians to offer
electronically-dispensed vouchers and
copay coupons right within their
ePrescribing process, thereby replacing
traditional (and costly) drug samples.
Services delivered across healthcare
industry’s largest point-of-prescribe
promotional network: 370+ electronic
health record (EHR) partners reaching
500K+ physicians.
• Multiple ROI studies confirm that the
OptimizeRx platform generates
results ranging from 300% to 1,200%
• Highly leveraged, low fixed costs
generates cash as revenues grow
Superior ROI
OptimizeRx eCoupon ROI vs.
Other Promotional Methods
1200%
900%
600%
300%
0%
-300%
-600%
OptimizeRx eCoupon
Most Effective
520%
eDetailing
Lowest ROI
Paid
Search
Average ROI
eCoupon
Highest ROI
OptimizeRx's Estimated Market
Penetration: 1%
Each market
share point
acquired worth
~$6 million2
~140 Million Rx
eCoupon Market
WPP: Major Strategic Investor
• WPP will leverage its large network of
pharmaceutical clients to help
OptimizeRx acquire more brands
Display
Large Market Opportunity1
• Large market opportunity: 2 billion eRx
transactional opportunities and point-ofcare marketing spend increasing, with
current estimated Rx eCoupon market
penetration of only 1% (~1.5M units)1
• WPP, the largest marketing firm in
the world, acquired 20%+ of
OptimizeRx in September 2015
1260%
ePrescribing Growth3
Prescription Renewal Responses
New Prescriptions
2 Billion
Recent News Highlights
Mar 8: Reported net revenue up 13% to
a record $2.3M in Q4 and up 7% to a
record $7.8M for the full year of 2016.
Jan 30: Appointed James Lang to Board
570M
326M
96M
57M
269M
474M
2010
2011
2016
Please note: this documents does not constitute an offer to sell, or a solicitation of an offer to buy, any security and may not be relied upon in connection with the purchase or sale of any security. Any such offer would only be made by means of formal
documents, the terms of which would govern in all respects. You should not rely on this presentation as the basis upon which to make any investment decision. ©OptimizeRx Corporation 2017. All Rights Reserved.
mrq = most recent quarter, ttm = trailing twelve months. *Strategic Ownership = WPP (LSE:WPP); Insider Holdings also includes WPP. Footnotes: 1) Company estimate. 2) Based on $4.00. Industry report conservatively made the following assumptions:100M in
prescriptions associated with coupons in 2010 or 11% of brand prescriptions, and Co-pay coupons to increase 15% per year to 500M in 2021. 3) The National Progress Report on ePrescribing & Safe-Rx Rankings, Surescripts, 2012.